Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376162 · ClinicalTrials.gov registry record · Phase 1
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
A Phase 1 study of Relapsed/Refractory KMT2A-r Acute Leukemia and Relapsed/Refractory NUP98-r Acute Leukemia, sponsored by PedAL BCU.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT06376162 is a Phase 1 study of Relapsed/Refractory KMT2A-r Acute Leukemia and Relapsed/Refractory NUP98-r Acute Leukemia that is actively recruiting participants, run by PedAL BCU. The registered enrollment target is 20 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT06376162, a Phase 1 study of Relapsed/Refractory KMT2A-r Acute Leukemia and Relapsed/Refractory NUP98-r Acute Leukemia, is actively recruiting participants, sponsored by PedAL BCU.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Cytarabine
- DRUG Ziftomenib
Study Locations (20)
Other
- Fondazione IRCCS San Gerardo dei Tintori (Ospedale San Gerardo) - Monza
- Prinses Maxima Centrum Kinderoncologie - Utrecht
- Hospital Universitari Vall d'Hebrón - Barcelona
- Hospital Infantil Universitario Niño Jesús - Madrid
California
- Children's Hospital Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376162
The ClinicalTrials.gov registry entry for NCT06376162 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PedAL BCU, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Relapsed/Refractory KMT2A-r Acute Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Fludarabine is the first listed.
NCT06376162 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06376162 about?
NCT06376162 is a clinical study titled "Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia". The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
What is the current status of trial NCT06376162?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-03-18. Estimated completion is 2027-01.
What conditions does trial NCT06376162 study?
This clinical trial studies the following conditions: Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia.
What interventions are being tested in trial NCT06376162?
The interventions under investigation include: Fludarabine (DRUG), Cytarabine (DRUG), Ziftomenib (DRUG).
Who is sponsoring clinical trial NCT06376162?
This trial is sponsored by PedAL BCU, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376162 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Relapsed/Refractory KMT2A-r Acute Leukemia
All registered trials for this condition
Relapsed/Refractory NUP98-r Acute Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.